Deferasirox

2 Drugs classified under this active ingredient

Iron Chelating Agent. Deferasirox 125mg, 250 mg, 500 mg.
Dispers. tabs. X 28.Transfusional iron overload: recomm. initial daily dose is 20 mg/kg body weight.
Non-transfusion-dependent thalassemia syndromes: recomm. initial daily dose is 10 mg/kg body weight. 
Chron. iron overload caused by blood transfus. (transfusional haemosiderosis) in ault and paed pts. (aged 2 years and over).
Chron. iron overload in pts with non-transfus.-depend. thalassaemia syndr. aged 10 years and older.
Chelat. ther. should only be init. when evident iron overload (liver iron concentr. [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consist. >800 μg/l). LIC is the preferred method of iron overload determin.
C/I: Hypersens. to the act. sub. or any excip. Combin. with other iron chelator therap. Pts with estim.creatinine clear. <60 ml/min. See lit.

Iron Chelating Agent. Deferasirox 125, 250, 500 mg.
DISPERS. TABS: 28. See lit.
Tmt. of chronic iron overload due to blood
transfuse. in adult & pediat. pts. (2 yrs and
over). Tmt. of chronic iron overload in pts.
with non-transfus.-depend. thalassemia
syndr. aged 10 yrs and older. Chelation ther.
should only be init. when there is evidence of iron overload (liver iron concentration [LIC] 5 mg Fe/g [dw] or serum ferritin consist. >800 g/l). LIC is the pref. method of iron overload determin. and should be used wherever available.
C/I: Hypersens. to the product. High risk
myelodysplastic syndrome pts. and pts.
with other hematology. and nonhematolog.
malign. who are not
expected to benefit from chelation ther.
due to the rapid progress. of their
disease. CLcr < 60 mL/min or serum cr >2
times the age-appropr. ULN. PLT counts
<50 x 109/L.